Endolymphatic hydrops induced by chronic administration of vasopressin.
Recently, many lines of evidence have supported the possibilities that vasopressin (VP) is closely linked to the formation of endolymphatic hydrops in Meniere's disease. In the present study, it was examined whether or not the chronic administration of VP might induce endolymphatic hydrops. For this purpose, histological studies and VP radioimmunoassay were independently performed in 20 and 40 guinea pigs, respectively. The degree of hydrops was quantitatively assessed by the increase ratio (IR) of the scala media area in the mid-modiolar sections of the cochlea. The IR was defined by the following equation: 100x(A-B)/B (A: the cross-sectional area of the bulging scala media; B: the no-bulging scala media, enclosed by an idealized straight Reissner's membrane). VP was administered at the rates of 200 microU/kg/min, 400 microU/kg/min and 1000 microU/kg/min for 1 week via the osmotic mini-pump. The IR of the total of the apical, second, third and basal turns (means+/-S.D.s) were 4.4+/-0.7, 10.4+/-1.8, 17.4+/-7.9 (n=10 ears, each) in respective doses of VP. Comparing with that of the control animals (5.2+/-1.7, n=10 ears), the area increased significantly in the VP dosage of 400 and 1000 microU/kg/min (Bonferroni's method, P<0.05). Plasma VP concentrations produced by the VP administration in these dosages were 2.2+/-0.4, 3.5+/-0.8 and 14.0+/-3.9 (n=10, each) pg/ml. Although 3.5 pg/ml is the upper limit of plasma VP concentration in normal human subjects, 14.0 pg/ml was almost the same concentration as those observed in the acute phase of Meniere's disease (Takeda et al., 1995). Therefore, the formation of endolymphatic hydrops in cases of Meniere's disease might be caused by high concentrations of plasma VP.
Takeda
T
T
Department of Otolaryngology, Kochi Medical School, Kohasu, Oko Nankoku, Kochi, Japan. takedat@kochi-ms.ac.jp
Takeda
S
S
Kitano
H
H
Okada
T
T
Kakigi
A
A
D000704:Analysis of Variance; D000818:Animals; D001127:Arginine Vasopressin / Q000008:administration & dosage / Q000009:adverse effects; D003051:Cochlea / Q000187:drug effects / Q000473:pathology; D003053:Cochlear Duct / Q000187:drug effects / Q000473:pathology; D004305:Dose-Response Relationship, Drug; D018159:Endolymphatic Hydrops / Q000139:chemically induced* / Q000473:pathology; D006168:Guinea Pigs; D014667:Vasopressins / Q000008:administration & dosage / Q000009:adverse effects* / Q000097:blood
D014667:Vasopressins; D001127:Arginine Vasopressin